RecruitingPhase 3NCT06465953
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut de Recherches Internationales Servier
- Intervention
- Ivosidenib(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Presbyterian / St. Luke'S Medical Center, Denver, Colorado, United States
- University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- MSKCC, New York, New York, United States
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Oncology Associates of Oregon, Eugene, Oregon, United States
- University of Texas UT Southwestern Comprehensive Cancer Center, Dallas, Texas, United States
- MD Anderson Cancer Centre, Houston, Texas, United States
- Royal Adelaide Hospital, Adelaide, Australia
- Monash Health, Clayton, Australia
- Northern Health, Epping, Australia
- Liverpool Hospital, Liverpool, Australia
- Sir Charles Gairdner Hospital, Nedlands, Australia
- Calvary Mater Newcastle, Waratah, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Servier Bio-Innovation LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06465953 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute